<DOC>
	<DOCNO>NCT01619189</DOCNO>
	<brief_summary>Transplantation allogeneic autologous limbal epithelial stem cell culture human amniotic membrane feeder eye total limbal deficiency . Prospective non-comparative monocentric study .</brief_summary>
	<brief_title>Cell Therapy Failure Syndromes Limbal Stem Cells</brief_title>
	<detailed_description>The limbal stem cell deficiency syndrome characterize invasion corneal surface epithelium conjunctival differentiation , , clinically , opacification vascularization corneal epithelium impaired corneal epithelial cicatrisation corneal ulcer may lead corneal perforation . When total , limbal deficiency syndrome cause major disability . Vision decrease largely legal threshold blindness . Overall , frequent etiology far complete loss limbal stem cell induce severe ocular burn . Until rather recent date , treatment possible pathology . Progress comprehension physiology corneal epithelium renewal make possible introduce therapeutic approach , i.e. , transplantation culture limbal stem cell retrieve healthy contralateral eye ( autograft , unilateral disease ) cadaveric donor eye ( allograft , bilateral disease unique eye ) . Techniques cell therapy first describe Italy , Asia USA positive clinical result . They different process prepare cell product transplant none answer safety criterion require French legislation . The investigator develop process prepare cell therapy product accept French regulation agency ( AFSSaPS ) clinical trial ( TC181 ) begin 2007 . The aim study ( 1 ) evaluation clinical result technique term improvement visual function , reduction handicap , improvement anatomical condition ocular surface restitution physiological function limbal epithelium ( 2 ) evaluation possible side effect . It biphasic monocentric non-comparative prospective study include , accord clinical response observe first phase ( plane Gehan , ß = 10 % ) , 15 50 voluntary patient unilateral bilateral total limbal deficiency . Patient follow-up 3 year . The expected minimal success rate 20 % allografts 40 % autograft . Monitoring ensured URC-Est . The graft prepared culture autologous allogeneic limbal epithelial cell limbal explants human amniotic membrane . The medical safety requirement relate transplantation tissue cell reach cell therapy product secure stage preparation conventional bacteriological fungal test viral bacterial PCR . The graft quality control transplantation . The main outcome measure survival graft epithelium ( Kaplan-Meier method ) define absence recurrence clinical sign limbal deficiency ( opacification corneal epithelium , irregularity corneal epithelium , surface corneal vascularization ) central cornea . The expected repercussion ( 1 ) restitution limbal epithelial function allow clear corneal epithelium obtain , superficial vascularization chronic epithelial defect , ( 2 ) improvement vision blind patient , ( 3 ) obtain vision high legal threshold blindness cell therapy subsequent corneal transplantation . If clinical trial make possible show effectiveness cell therapy technique , request authorization process make AFSSaPS routine use .</detailed_description>
	<criteria>Patient age 18 70 year Informed consent . Unilateral bilateral limbal deficiency diffuse opacification corneal epithelium , superficial ( superficial deep ) corneal vascularization , irregular corneal epithelial surface slitlamp examination fluorescein , either associate chronic epithelial defect Visual acuity eye treat &lt; 20/20 . Absence de kératinization ocular surface . Schirmer test &gt; 0 3 minute . For autograft : sérology HIV , HCV , HBs Age &lt; 18 &gt; 70 . Absence inform consent imformed consent possible . Partial limbal deficiency ( healthy corneal epithelium persistant least one zone ) . Previous treatment limbal deficiency limbal transplantation amniotic membrane transplantation last 12 month . Conjunctival stem cell deficiency ( xerophtalmia , keratinization ocular surface ) . Local anesthesia impossible . Immune keratitis control medical treatment . Ocular burn last 2 week . Corneal anesthesia . Pregnancy , breastfeed . Allergy steroid eyedrop . Active fungal keratitis . For autograft : risk factor rabbies CreutzfeldtJacob disease , serology HIV + , VHC + , HBs+ . Followup possible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Cell therapy</keyword>
	<keyword>Limbal deficiency</keyword>
	<keyword>Limbal stem cell</keyword>
	<keyword>Transplantation</keyword>
</DOC>